Area of research
Otorhinolaryngology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Head and Neck Cancer Studies, Head and Neck Surgical Oncology, Oral health in cancer treatment, and Lung Cancer Treatments and Mutations.
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer
Early Dynamics of Circulating Tumor HPV-DNA with Neoadjuvant Chemotherapy and Response-Adapted De-escalation in Human Papillomavirus–Associated Oropharyngeal Cancer
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV<sup>+</sup> Oropharyngeal Cancer
Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.
Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment
Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial.
Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience
Adjuvant treatment for high‐risk salivary gland malignancies and prognostic stratification based on a 20‐year single institution experience
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer
Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience
Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer
Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer
Lymph node density—Prognostic value in head and neck cancer
Race and competing mortality in advanced head and neck cancer
DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN).